No abstract

with a diagnosis of germ-line BRCA ½ mutation and who underwent breast cancer risk-reducing surgery. The occurrence of occult carcinoma was analysed. A descriptive study of these patients was performed. All statistical analysis was performed with Stata/IC 13.0 for Windows. Result(s)* During the study period a total of 168 patients with BRCA ½ mutation were diagnosed and breast risk-reducing surgery was performed in 81 of them (48.2%).In 61.7% (n=50) of the cases, prophylactic surgery was performed after the diagnosis of bilateral breast cancer. Bilateral breast and in 7.4 (n=6) ovarian cancer. In 58.0% (n=47) the mutation was BRCA 1 and in 42% (n=34) BRCA 2. In 39.5% (n=32) the mastectomy performed was nipple sparing and in 60.5% (n=49) simple. Breast reconstruction was performed after surgery in 93.8% (n=76) of cases. Definitive histopathological examination showed ductal carcinoma insitu in 3.7% (n=3) of cases, and infiltrating carcinoma in 1.2% (n=1). Conclusion* In our case series, approximately half of the patients carrying BRCA mutation have opted for breast cancer risk-reducing surgery, with a proportion of incidental carcinomas between 1-3% in the mastectomy surgical specimens. Therefore, we can conclude that in patients carrying BRCA1/2 mutation, prophylactic mastectomy is effective in reducing the risk of breast cancer.

associated with advanced FIGO stage, suboptimal cytoreduction and application of chemotherapy. In small cohorts, the confirmation in multivariate analysis stays difficult, although trends can be shown. For this aggressive but rare tumour international prospective, multicentric databases are needed to provide more concordant data. Consequent and standardised immunohistopathological workup as a basis for molecular tumour boards is worthwhile. More randomised controlled trials on adjuvant therapy are necessary to give physicians convincing treatment options especially in the recurrent situation.

apatinib combined with chemotherapy plus PD-1 antibody drug (2/26), and apatinib combined with PD-1 antibody drug (9/26) and apatinib combined with chemotherapy plus radiotherapy (1/26). The median follow-up time was 5 months. The ORR and DCR were 47.3%(9/19) and 94.7%(18/19). The median PFS was not reached.In addition, 23 pts with ovarian cancer were enrolled in this study. Among them 15 pts were platinum-sensitive, 8 pts were platinum-resistant. The treatment regimens were: apatinib combined with chemotherapy (19/23), apatinib monotherapy (1/23), apatinib combined with chemotherapy drugs plus PD-1 antibody drug (1/23), apatinib combined with PD-1 antibody drug (1/23) and apatinib combined with PARPi (1/23). The median follow-up time was 6 months.The median PFS was 4 months.The ORR and DCR was 14.3%(3/21) and 85.7%(18/ 21).In this real-world study, the incidence of adverse reactions of ovarian cancer and cervical cancer was 79.6%. Grade 3 neutropenia, leukopenia, anemia, proteinuria and thrombocytopenia were observed in 2, 1, 5, 2 and 3 pts. Conclusion* In this real-world study, apatinib showed a favorable efficacy and safety profile in pts with gynecological cancer. It might lead to better survival benefit in treatment for gynecological cancer pts.

No abstract